Ito M, et al. (2019) Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Cell Commun Signal 17, 137 31660987

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S144-p - PAK1 (human) ▲

Modsite: sNsQKyMsFtDksAE SwissProt Entrez-Gene Orthologous residues PAK1 (human): S144‑p, PAK1 (mouse): S144‑p, PAK1 (rat): S144‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell squamous cell lung carcinoma Relevant cell lines - cell types - tissues:  HCC827 (pulmonary), NCI-H23 (pulmonary), NCI-H520 (squamous) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  Mouse xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes osimertinib no change compared to control IPA-3, osimertinib no change compared to control IPA-3 decrease Auranofin decrease Auranofin, IPA-3 decrease OTSSP167 decrease Auranofin, OTSSP167 decrease Auranofin, Trametinib decrease Downstream Regulation Effect of modification (process):  carcinogenesis, induced, cell growth, induced Comments:  Inhibitors decreased the tumor growth by inhibiting the phosphorylation Associated Diseases Diseases Alterations Comments non-small cell lung cancer increased Inhibitors of PAK1-inhibits the tumor growth

S204-p - PAK1 (human) ▲

Modsite: tKsVyTRsVIEPLPV SwissProt Entrez-Gene Orthologous residues PAK1 (human): S204‑p, PAK1 (mouse): S204‑p, PAK1 (rat): S203‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell squamous cell lung carcinoma Relevant cell lines - cell types - tissues:  HCC827 (pulmonary), NCI-H23 (pulmonary), NCI-H520 (squamous) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  Mouse xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes OTSSP167 decrease Auranofin decrease Auranofin, OTSSP167 decrease IPA-3 decrease Auranofin, IPA-3 decrease osimertinib decrease IPA-3, osimertinib decrease Downstream Regulation Effect of modification (process):  carcinogenesis, induced, cell growth, induced Comments:  Inhibitors decreased the tumor growth by inhibiting the phosphorylation Associated Diseases Diseases Alterations Comments non-small cell lung cancer increased Inhibitors of PAK1-inhibits the tumor growth

T212-p - PAK1 (human) ▲

Modsite: VIEPLPVtPtRDVAt SwissProt Entrez-Gene Orthologous residues PAK1 (human): T212‑p, PAK1 (mouse): T212‑p, PAK1 (rat): T211‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell squamous cell lung carcinoma Relevant cell lines - cell types - tissues:  HCC827 (pulmonary), NCI-H23 (pulmonary), NCI-H520 (squamous) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  Mouse xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes OTSSP167 decrease Auranofin decrease Auranofin, OTSSP167 decrease IPA-3 decrease Auranofin, IPA-3 decrease osimertinib decrease IPA-3, osimertinib decrease Downstream Regulation Effect of modification (process):  carcinogenesis, induced, cell growth, induced Comments:  Inhibitors decreased the tumor growth by inhibiting the phosphorylation Associated Diseases Diseases Alterations Comments non-small cell lung cancer increased Inhibitors of PAK1-inhibits the tumor growth

T423-p - PAK1 (human) ▲

Modsite: PEQSkRstMVGtPYW SwissProt Entrez-Gene Orthologous residues PAK1 (human): T423‑p, PAK1 (mouse): T423‑p, PAK1 (rat): T422‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell squamous cell lung carcinoma Relevant cell lines - cell types - tissues:  HCC827 (pulmonary), NCI-H23 (pulmonary), NCI-H520 (squamous) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  Mouse xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes osimertinib no change compared to control IPA-3, osimertinib no change compared to control IPA-3 decrease Auranofin decrease Auranofin, IPA-3 decrease OTSSP167 decrease Auranofin, OTSSP167 decrease Downstream Regulation Effect of modification (process):  carcinogenesis, induced, cell growth, induced Comments:  Inhibitors decreased the tumor growth by inhibiting the phosphorylation Associated Diseases Diseases Alterations Comments non-small cell lung cancer increased Inhibitors of PAK1-inhibits the tumor growth